Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Gleolan
Synonyms :
ALA, aminolevulinic acid oral
Class :
Contrast media
Brand Name :
Gleolan
Synonyms :
ALA, aminolevulinic acid oral
Class :
Contrast media
Dosage Forms & StrengthsÂ
Lyophilized powder for oral solutionÂ
30mg/mlÂ
Take 20 mg/kg orally approximately 3 hours prior to induction of anesthesia
Dosage Modifications
Renal impairment: dose modification not known
Hepatic impairment: study not conducted
Dosage Considerations
Only neurosurgeons who have completed a course on the use of fluorescence in surgery should use it
Safety and efficacy not determined Â
Refer to adult dosingÂ
aminolevulinic acid oral, ciprofloxacin, increases toxicity of either drug because of pharmacodynamic synergism. Avoid or use alternate drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during the perioperative period.
When both drugs are combined, there may be an increased risk of adverse effect 
may enhance the toxic effects of demeclocycline
may enhance the toxic effects of doxycycline
It may enhance the risk of adverse effects when combined with Glucocorticoids
It may enhance the risk of adverse effects when combined with Glucocorticoids
It may enhance the risk of adverse effects when combined with Glucocorticoids
It may enhance the risk of adverse effects when combined with Glucocorticoids
It may enhance the risk of adverse effects when combined with Glucocorticoids
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
photosensitizing agents increase the effect of verteporfin
photosensitizing agents increase the effect of porfimer
photosensitizing agents increase the effect of methoxsalen
Actions and spectrum:Â
Endogenous aminolevulinic acid is produced by the mitochondria from succinyl-CoA and glycine; exogenous administration causes tumor cells to accumulate the aminolevulinic acid metabolite PpIX.Â
Frequency definedÂ
Headache (2.7%)Â
Seizure (1.9%)Â
Monoparesis (1.3%)Â
Aphasia (8%)Â
Hypoesthesia (1.1%)Â
Cerebral edema Â
Frequency not definedÂ
Induced eye injuryÂ
Increased photosensitivityÂ
Adverse reaction of ophthalmicÂ
Irritation of mucous membraneÂ
HypotensionÂ
Inflammation at the site of applicationÂ
FatigueÂ
Episodes of transient amnesiaÂ
Black Box Warning Â
Do not administer phototoxic drugs before or after taking aminolevulinic acidÂ
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
PorphyriaÂ
Cardiopulmonary resuscitationÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: Data not availableÂ
Lactation:Â Â
The excretion of aminolevulinic acid into human milk is not knownÂ
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Pharmacodynamics:Â
In glioma surgery, tumor tissue is visible as red fluorescence when an operating microscope equipped with a blue light source and filters for 375–440 nm excitation light and 620–710 nm observation light is used. Tumor tissue without adequate PpIX concentrations appears blue.Â
Pharmacokinetics:Â
AbsorptionÂ
The absolute bioavailability of aminolevulinic acid is 100%, with a peak concentration of 0.8hourÂ
DistributionÂ
12% of the drug is bound to proteinÂ
MetabolismÂ
It is metabolized to PpIXÂ
Elimination and excretionÂ
34% of the drug is eliminated through urine Â
Half-life:Â
0.9hour for aminolevulinic acidÂ
3.6hour for PpIXÂ
Administration:Â
For oral use onlyÂ
Before administration, reconstitute the powderÂ
Patient information leafletÂ
Generic Name: aminolevulinic acid Â
Why do we use aminolevulinic acid?Â
Aminolevulinic acid is used to diagnose glioma in patients for identifying malignant tissue, especially in patients suspected of WHO grade III or IV on preoperative imaging.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
